Metabolic and Hemodynamic Effects of the Inhibitors of Type 2 Sodium Glucose Co-transporters (ISGLT2) in Diabetic Patients With Heart Failure
Metabolic and Hemodynamic Effects of the Inhibitors of Type 2 Sodium Glucose Co-transporters (ISGLT2) in Diabetic Patients With Heart Failure
Inhibitors of the type 2 sodium-glucose co-transporter (iSGLT2) may improve the metabolic and
 hemodynamic profile in patients with DM2 and heart failure.
Inclusion Criteria:

 -  Type 2 Diabetes

 -  HbA1c> 6.5%

 -  Estimated GF> 45 ml / min

 -  BMI: ≥25 Kg / m2

 -  Stable pharmacological treatment of Heart Failure in the last 3 months

 Exclusion Criteria:

 -  Diabetes type 1 or type LADA (presence of antibodies against GAD and/or IA-2 positive)

 -  DM2 with C-peptide <1 ng / mL

 -  GEF <45 ml / min

 -  Recurrent urinary tract infections